UNSPSC 51434931: Hydrochlorothiazide/losartan

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434931 Hydrochlorothiazide/losartan, a Commodity code, covers individual pharmaceutical products supplied to state and local government agencies, health departments, fire rescue services, and healthcare systems. State and local buyers procure specific medications under this code for emergency medical services, pharmacy benefit programs, and institutional healthcare delivery. The issuing bodies include municipal fire departments, state health and human services agencies, and multistate cooperative purchasing alliances representing multiple state and local jurisdictions. Solicitations typically specify exact medication formulations, unit counts, expiration-date requirements, and delivery timelines; pricing is firm and frequently includes shipping, taxes, and warranty provisions covering defects and expired-material replacement. Vendors must comply with cGMP, FDA requirements, OSHA Hazard Communication Standards for Safety Data Sheets, and Drug Supply Chain Security Act (DSCSA) compliance, and must maintain appropriate insurance coverage and contractual relationships with authorized pharmaceutical wholesalers.

Recent activity spans Florida, Texas, and a multistate cooperative covering Minnesota and Oregon. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26P00188) on April 24, 2026, for Advanced Life Support Medications to be used by Tampa Fire Rescue, with a due date of April 8, 2026, an estimated contract value of $40,000, and a one-year term with optional two-year renewals; the solicitation applied a Small Local Business Enterprise (SLBE) sheltered market designation with a 5 percent bid discount. The Texas Health and Human Services Commission issued an RFI (No. HHS0017013) posted April 3, 2026, to gather vendor capabilities for a direct-to-manufacturer prescriptions program, signaling early-stage state-level pharmacy benefit restructuring. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with effective dates of July 1, 2026, requiring vendors to work through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson), maintain specified insurance thresholds, and accept a 3 percent administrative fee with performance penalties of $200 to $1,500 per violation.